Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

86.61
+3.023.61%
Volume:1.86M
Turnover:160.86M
Market Cap:11.36B
PE:-26.08
High:89.25
Open:84.97
Low:84.51
Close:83.59
52wk High:120.74
52wk Low:36.36
Shares:131.17M
Float Shares:126.00M
Volume Ratio:1.07
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3203
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-15.59%
PB:-114.39
PE(LYR):-26.08

Loading ...

Guardant Health Inc. to Report Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Jan 30

Psychedelic: Analyst raises Compass, Definium, GH Research price targets

TIPRANKS
·
Jan 29

Guardant Health Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 27

FDA Approves New Colorectal Cancer Use For Guardant360 Might Change The Case For Investing In Guardant Health (GH)

Simply Wall St.
·
Jan 24

Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Guardant Health (GH)

TIPRANKS
·
Jan 24

Leerink sees Court ruling as small win for Guardant, no change to patent risk

TIPRANKS
·
Jan 24

GH Research price target raised to $40 from $33 at RBC Capital

TIPRANKS
·
Jan 24

GH Research Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jan 23

RBC Raises Price Target on GH Research to $40 From $33, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 23

RBC Capital Remains a Buy on GH Research (GHRS)

TIPRANKS
·
Jan 23

Guardant Health Chief People Officer Terilyn J. Monroe Reports Sale of Common Shares

Reuters
·
Jan 23

FDA Approves Guardant360 CDx as Companion Diagnostic for BRAFTOVI Combination in BRAF V600E-Mutant Metastatic Colorectal Cancer

Reuters
·
Jan 22

Guardant Health Receives FDA Approval for Guardant360® Cdx as Companion Diagnostic for Braftovi® (Encorafenib) Combination in Patients With Braf V600e-Mutant Metastatic Colorectal Cancer

THOMSON REUTERS
·
Jan 22

Guardant Health announces multi-year strategic agreement with Merck

TIPRANKS
·
Jan 20

Guardant Health projects 2025 revenue to reach $981 million

Reuters
·
Jan 20

BRIEF-Guardant Health Announces Multi-Year Strategic Collaboration Agreement With Merck

Reuters
·
Jan 19

Guardant Health Partners with Merck to Develop and Commercialize Cancer Therapies

Reuters
·
Jan 19

Guardant Health Announces Multi-Year Strategic Collaboration Agreement With Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

THOMSON REUTERS
·
Jan 19

Guardant Health Inc - Partnership for Global Commercialization of Drugs and Companion Diagnostics in US, Asia-Pacific, UK, EU Markets

THOMSON REUTERS
·
Jan 19

Supersize CEO Pay Packages Aren't Paying Off for Shareholders -- WSJ

Dow Jones
·
Jan 17